Quality of life with encorafenib plus cetuximab with or without binimetinib treatment in patients with BRAF V600E-mutant metastatic colorectal cancer: patient-reported outcomes from BEACON CRC
- Author(s)
- Kopetz, S; Grothey, A; Van Cutsem, E; Yaeger, R; Wasan, H; Yoshino, T; Desai, J; Ciardiello, F; Loupakis, F; Hong, YS; Steeghs, N; Guren, TK; Arkenau, HT; Garcia-Alfonso, P; Belani, A; Zhang, X; Tabernero, J;
- Details
- Publication Year 2022-06,Volume 7,Issue #3,Page 100477
- Journal Title
- ESMO Open
- Publication Type
- Research article
- Abstract
- BACKGROUND: In the BEACON CRC study (NCT02928224), encorafenib plus cetuximab with binimetinib 9.3 versus 5.9 months; hazard ratio (HR) [95% confidence interval (CI)]: 0.60 [0.47-0.75] or without binimetinib [9.3 versus 5.9 months; HR (95% CI): 0.61 (0.48-0.77)] significantly improved overall survival (OS) compared with the previous standard of care (control) in patients with BRAF V600E metastatic colorectal cancer (mCRC). Quality of life (QoL) was a secondary endpoint, assessed using validated instruments. PATIENTS AND METHODS: BEACON CRC was a randomized, open-label, phase III study comparing encorafenib plus cetuximab with or without binimetinib and the investigator's choice of irinotecan plus cetuximab or FOLFIRI plus cetuximab (chemotherapy control) in patients with previously treated BRAF V600E mCRC. Patient-reported QoL assessments included the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC) and Functional Assessment of Cancer Therapy-Colorectal (FACT-C). The primary outcome for these tools was time to definitive 10% deterioration. RESULTS: Encorafenib plus cetuximab, both with and without binimetinib, was associated with longer median times to definitive 10% deterioration versus the control group in the EORTC Global Health Status scale [HR (95% CI): 0.65 (0.52-0.80) versus 0.61 (0.49-0.75), respectively] and the FACT-C functional well-being subscale [HR (95% CI): 0.62 (0.50-0.76) versus 0.58 (0.47-0.72), respectively]. Consistent results were observed across all subscales of the EORTC and FACT-C instruments. QoL was generally maintained during treatment for the global EORTC and FACT-C scales. CONCLUSIONS: In addition to improving OS, encorafenib plus cetuximab with or without binimetinib delays QoL decline in previously treated patients with BRAF V600E-mutant mCRC.
- Keywords
- *Antineoplastic Agents/therapeutic use; Antineoplastic Combined Chemotherapy Protocols/therapeutic use; Benzimidazoles; Carbamates; Cetuximab/therapeutic use; *Colorectal Neoplasms/drug therapy/genetics; Humans; Mutation; Patient Reported Outcome Measures; *Proto-Oncogene Proteins B-raf/genetics; Quality of Life; Sulfonamides; Beacon crc; cetuximab; colorectal cancer; encorafenib; patient-reported outcomes
- Department(s)
- Medical Oncology
- PubMed ID
- 35653981
- Publisher's Version
- https://doi.org/10.1016/j.esmoop.2022.100477
- Open Access at Publisher's Site
https://doi.org/10.1016/j.esmoop.2022.100477- Terms of Use/Rights Notice
- Refer to copyright notice on published article.
Creation Date: 2024-12-20 05:36:46
Last Modified: 2024-12-20 05:37:53